Kaiyao-B (02105.HK) announced on June 26 that the group has launched Phase I clinical trials of LAE102 in China and has completed the first subject dose. This Phase I clinical trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, and pharmacokinetics of this therapy. The group is committed to bringing this precision treatment to overweight and obese patients who need new treatment options to achieve high-quality weight control.
来凯医药-B(02105.HK)：LAE102针对肥胖症治疗的I期临床试验完成首例受试者用药
LAE102 completed the first dose in Phase I clinical trial for obesity treatment at Laike Pharmaceutical-B (02105.HK).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.